BioCryst Pharma (BCRX) Misses Q4 EPS by 6c; offers outlook

BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.13), $0.06 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $131.53 million versus the consensus estimate of $127.17 million.

OUTLOOK

Financial Outlook for 2025

Based on the early signs we are seeing that many more of our Medicare patients are able to afford paid therapy in 2025, and the strong patient demand for ORLADEYO to start the year, the company has increased its full year 2025 outlook for global net ORLADEYO revenue to between $535 million and $550 million (previously $515 million to $535 million). The company now expects full year 2025 total revenue (including RAPIVAB® (peramivir injection)) will be between $560 million and $575 million (previously $540 million to $560 million).

The increased guidance for ORLADEYO revenues in 2025 also results in an increase in related operating expenses, primarily related to cost of goods sold, distribution costs and higher incentive compensation. The company reiterates the previously provided 2025 non-GAAP operating expense outlook range of $425 million to $435 million (not including stock-based compensation). The revenue related operating expense increases are captured at the higher end of this range.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Pacific Booker Minerals Inc. Adopts Advance Notice Policy for Director Elections
• Alphabet to replace Verizon in the Dow Jones Industrial Average